ARTICLE | Company News

1ST Bio partners with Neuraly for PD

December 1, 2017 10:04 PM UTC

1ST Bio Therapeutics Inc. (Seongnam, South Korea) partnered with Neuraly Inc. to co-develop brain penetrant inhibitors of ABL proto-oncogene 1 non-receptor tyrosine kinase (ABL; ABL1) to treat Parkinson's disease. Neuraly spun out of Johns Hopkins University.

1ST Biotherapeutics will be responsible for preclinical development, and Neuraly will test the candidates in various preclinical models of PD. The companies said their goal is to submit an IND to FDA next year. ...